Report cover image

Global Bacille Calmette-Guerin Vaccine Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 199 Pages
SKU # APRC20359504

Description

Summary

According to APO Research, the global Bacille Calmette-Guerin Vaccine market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Bacille Calmette-Guerin Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Bacille Calmette-Guerin Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Bacille Calmette-Guerin Vaccine market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Bacille Calmette-Guerin Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Bacille Calmette-Guerin Vaccine market include China National Biotec, Merck, Taj Pharmaceuticals, Serum Institute of India, Queen Saovabha Mem. Inst, Microgen, Japan BCG Lab, IVAC – Institute of Vaccines and Medical Biologicals and GreenSignal Bio Pharma, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Bacille Calmette-Guerin Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Bacille Calmette-Guerin Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Bacille Calmette-Guerin Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Bacille Calmette-Guerin Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Bacille Calmette-Guerin Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Bacille Calmette-Guerin Vaccine sales, projected growth trends, production technology, application and end-user industry.

Bacille Calmette-Guerin Vaccine Segment by Company

China National Biotec
Merck
Taj Pharmaceuticals
Serum Institute of India
Queen Saovabha Mem. Inst
Microgen
Japan BCG Lab
IVAC – Institute of Vaccines and Medical Biologicals
GreenSignal Bio Pharma
Biomed Lublin
BioFarma
Ataulpho de Paiva
AJ Vaccines
Bacille Calmette-Guerin Vaccine Segment by Type

Immune Vaccine
Therapy Vaccine
Bacille Calmette-Guerin Vaccine Segment by Application

Self-Procurement
UNICEF
Other
Bacille Calmette-Guerin Vaccine Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Bacille Calmette-Guerin Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Bacille Calmette-Guerin Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Bacille Calmette-Guerin Vaccine significant trends, drivers, influence factors in global and regions.
6. To analyze Bacille Calmette-Guerin Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Bacille Calmette-Guerin Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Bacille Calmette-Guerin Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Bacille Calmette-Guerin Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Bacille Calmette-Guerin Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Bacille Calmette-Guerin Vaccine industry.
Chapter 3: Detailed analysis of Bacille Calmette-Guerin Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Bacille Calmette-Guerin Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Bacille Calmette-Guerin Vaccine in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Table of Contents

199 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Bacille Calmette-Guerin Vaccine Sales Value (2020-2031)
1.2.2 Global Bacille Calmette-Guerin Vaccine Sales Volume (2020-2031)
1.2.3 Global Bacille Calmette-Guerin Vaccine Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Bacille Calmette-Guerin Vaccine Market Dynamics
2.1 Bacille Calmette-Guerin Vaccine Industry Trends
2.2 Bacille Calmette-Guerin Vaccine Industry Drivers
2.3 Bacille Calmette-Guerin Vaccine Industry Opportunities and Challenges
2.4 Bacille Calmette-Guerin Vaccine Industry Restraints
3 Bacille Calmette-Guerin Vaccine Market by Company
3.1 Global Bacille Calmette-Guerin Vaccine Company Revenue Ranking in 2024
3.2 Global Bacille Calmette-Guerin Vaccine Revenue by Company (2020-2025)
3.3 Global Bacille Calmette-Guerin Vaccine Sales Volume by Company (2020-2025)
3.4 Global Bacille Calmette-Guerin Vaccine Average Price by Company (2020-2025)
3.5 Global Bacille Calmette-Guerin Vaccine Company Ranking (2023-2025)
3.6 Global Bacille Calmette-Guerin Vaccine Company Manufacturing Base and Headquarters
3.7 Global Bacille Calmette-Guerin Vaccine Company Product Type and Application
3.8 Global Bacille Calmette-Guerin Vaccine Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Bacille Calmette-Guerin Vaccine Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Bacille Calmette-Guerin Vaccine Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Bacille Calmette-Guerin Vaccine Market by Type
4.1 Bacille Calmette-Guerin Vaccine Type Introduction
4.1.1 Immune Vaccine
4.1.2 Therapy Vaccine
4.2 Global Bacille Calmette-Guerin Vaccine Sales Volume by Type
4.2.1 Global Bacille Calmette-Guerin Vaccine Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Bacille Calmette-Guerin Vaccine Sales Volume by Type (2020-2031)
4.2.3 Global Bacille Calmette-Guerin Vaccine Sales Volume Share by Type (2020-2031)
4.3 Global Bacille Calmette-Guerin Vaccine Sales Value by Type
4.3.1 Global Bacille Calmette-Guerin Vaccine Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Bacille Calmette-Guerin Vaccine Sales Value by Type (2020-2031)
4.3.3 Global Bacille Calmette-Guerin Vaccine Sales Value Share by Type (2020-2031)
5 Bacille Calmette-Guerin Vaccine Market by Application
5.1 Bacille Calmette-Guerin Vaccine Application Introduction
5.1.1 Self-Procurement
5.1.2 UNICEF
5.1.3 Other
5.2 Global Bacille Calmette-Guerin Vaccine Sales Volume by Application
5.2.1 Global Bacille Calmette-Guerin Vaccine Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Bacille Calmette-Guerin Vaccine Sales Volume by Application (2020-2031)
5.2.3 Global Bacille Calmette-Guerin Vaccine Sales Volume Share by Application (2020-2031)
5.3 Global Bacille Calmette-Guerin Vaccine Sales Value by Application
5.3.1 Global Bacille Calmette-Guerin Vaccine Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Bacille Calmette-Guerin Vaccine Sales Value by Application (2020-2031)
5.3.3 Global Bacille Calmette-Guerin Vaccine Sales Value Share by Application (2020-2031)
6 Bacille Calmette-Guerin Vaccine Regional Sales and Value Analysis
6.1 Global Bacille Calmette-Guerin Vaccine Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Bacille Calmette-Guerin Vaccine Sales by Region (2020-2031)
6.2.1 Global Bacille Calmette-Guerin Vaccine Sales by Region: 2020-2025
6.2.2 Global Bacille Calmette-Guerin Vaccine Sales by Region (2026-2031)
6.3 Global Bacille Calmette-Guerin Vaccine Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Bacille Calmette-Guerin Vaccine Sales Value by Region (2020-2031)
6.4.1 Global Bacille Calmette-Guerin Vaccine Sales Value by Region: 2020-2025
6.4.2 Global Bacille Calmette-Guerin Vaccine Sales Value by Region (2026-2031)
6.5 Global Bacille Calmette-Guerin Vaccine Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Bacille Calmette-Guerin Vaccine Sales Value (2020-2031)
6.6.2 North America Bacille Calmette-Guerin Vaccine Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Bacille Calmette-Guerin Vaccine Sales Value (2020-2031)
6.7.2 Europe Bacille Calmette-Guerin Vaccine Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Bacille Calmette-Guerin Vaccine Sales Value (2020-2031)
6.8.2 Asia-Pacific Bacille Calmette-Guerin Vaccine Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Bacille Calmette-Guerin Vaccine Sales Value (2020-2031)
6.9.2 South America Bacille Calmette-Guerin Vaccine Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Bacille Calmette-Guerin Vaccine Sales Value (2020-2031)
6.10.2 Middle East & Africa Bacille Calmette-Guerin Vaccine Sales Value Share by Country, 2024 VS 2031
7 Bacille Calmette-Guerin Vaccine Country-level Sales and Value Analysis
7.1 Global Bacille Calmette-Guerin Vaccine Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Bacille Calmette-Guerin Vaccine Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Bacille Calmette-Guerin Vaccine Sales by Country (2020-2031)
7.3.1 Global Bacille Calmette-Guerin Vaccine Sales by Country (2020-2025)
7.3.2 Global Bacille Calmette-Guerin Vaccine Sales by Country (2026-2031)
7.4 Global Bacille Calmette-Guerin Vaccine Sales Value by Country (2020-2031)
7.4.1 Global Bacille Calmette-Guerin Vaccine Sales Value by Country (2020-2025)
7.4.2 Global Bacille Calmette-Guerin Vaccine Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2020-2031)
7.5.2 USA Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2020-2031)
7.6.2 Canada Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2020-2031)
7.8.2 Germany Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2020-2031)
7.9.2 France Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2024 VS 2031
7.9.3 France Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2020-2031)
7.11.2 Italy Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2020-2031)
7.12.2 Spain Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2020-2031)
7.13.2 Russia Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2020-2031)
7.16.2 China Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2024 VS 2031
7.16.3 China Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2020-2031)
7.17.2 Japan Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2020-2031)
7.19.2 India Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2024 VS 2031
7.19.3 India Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2020-2031)
7.20.2 Australia Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2020-2031)
7.24.2 Chile Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2020-2031)
7.26.2 Peru Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2020-2031)
7.28.2 Israel Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2020-2031)
7.29.2 UAE Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2020-2031)
7.31.2 Iran Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 China National Biotec
8.1.1 China National Biotec Comapny Information
8.1.2 China National Biotec Business Overview
8.1.3 China National Biotec Bacille Calmette-Guerin Vaccine Sales, Value and Gross Margin (2020-2025)
8.1.4 China National Biotec Bacille Calmette-Guerin Vaccine Product Portfolio
8.1.5 China National Biotec Recent Developments
8.2 Merck
8.2.1 Merck Comapny Information
8.2.2 Merck Business Overview
8.2.3 Merck Bacille Calmette-Guerin Vaccine Sales, Value and Gross Margin (2020-2025)
8.2.4 Merck Bacille Calmette-Guerin Vaccine Product Portfolio
8.2.5 Merck Recent Developments
8.3 Taj Pharmaceuticals
8.3.1 Taj Pharmaceuticals Comapny Information
8.3.2 Taj Pharmaceuticals Business Overview
8.3.3 Taj Pharmaceuticals Bacille Calmette-Guerin Vaccine Sales, Value and Gross Margin (2020-2025)
8.3.4 Taj Pharmaceuticals Bacille Calmette-Guerin Vaccine Product Portfolio
8.3.5 Taj Pharmaceuticals Recent Developments
8.4 Serum Institute of India
8.4.1 Serum Institute of India Comapny Information
8.4.2 Serum Institute of India Business Overview
8.4.3 Serum Institute of India Bacille Calmette-Guerin Vaccine Sales, Value and Gross Margin (2020-2025)
8.4.4 Serum Institute of India Bacille Calmette-Guerin Vaccine Product Portfolio
8.4.5 Serum Institute of India Recent Developments
8.5 Queen Saovabha Mem. Inst
8.5.1 Queen Saovabha Mem. Inst Comapny Information
8.5.2 Queen Saovabha Mem. Inst Business Overview
8.5.3 Queen Saovabha Mem. Inst Bacille Calmette-Guerin Vaccine Sales, Value and Gross Margin (2020-2025)
8.5.4 Queen Saovabha Mem. Inst Bacille Calmette-Guerin Vaccine Product Portfolio
8.5.5 Queen Saovabha Mem. Inst Recent Developments
8.6 Microgen
8.6.1 Microgen Comapny Information
8.6.2 Microgen Business Overview
8.6.3 Microgen Bacille Calmette-Guerin Vaccine Sales, Value and Gross Margin (2020-2025)
8.6.4 Microgen Bacille Calmette-Guerin Vaccine Product Portfolio
8.6.5 Microgen Recent Developments
8.7 Japan BCG Lab
8.7.1 Japan BCG Lab Comapny Information
8.7.2 Japan BCG Lab Business Overview
8.7.3 Japan BCG Lab Bacille Calmette-Guerin Vaccine Sales, Value and Gross Margin (2020-2025)
8.7.4 Japan BCG Lab Bacille Calmette-Guerin Vaccine Product Portfolio
8.7.5 Japan BCG Lab Recent Developments
8.8 IVAC – Institute of Vaccines and Medical Biologicals
8.8.1 IVAC – Institute of Vaccines and Medical Biologicals Comapny Information
8.8.2 IVAC – Institute of Vaccines and Medical Biologicals Business Overview
8.8.3 IVAC – Institute of Vaccines and Medical Biologicals Bacille Calmette-Guerin Vaccine Sales, Value and Gross Margin (2020-2025)
8.8.4 IVAC – Institute of Vaccines and Medical Biologicals Bacille Calmette-Guerin Vaccine Product Portfolio
8.8.5 IVAC – Institute of Vaccines and Medical Biologicals Recent Developments
8.9 GreenSignal Bio Pharma
8.9.1 GreenSignal Bio Pharma Comapny Information
8.9.2 GreenSignal Bio Pharma Business Overview
8.9.3 GreenSignal Bio Pharma Bacille Calmette-Guerin Vaccine Sales, Value and Gross Margin (2020-2025)
8.9.4 GreenSignal Bio Pharma Bacille Calmette-Guerin Vaccine Product Portfolio
8.9.5 GreenSignal Bio Pharma Recent Developments
8.10 Biomed Lublin
8.10.1 Biomed Lublin Comapny Information
8.10.2 Biomed Lublin Business Overview
8.10.3 Biomed Lublin Bacille Calmette-Guerin Vaccine Sales, Value and Gross Margin (2020-2025)
8.10.4 Biomed Lublin Bacille Calmette-Guerin Vaccine Product Portfolio
8.10.5 Biomed Lublin Recent Developments
8.11 BioFarma
8.11.1 BioFarma Comapny Information
8.11.2 BioFarma Business Overview
8.11.3 BioFarma Bacille Calmette-Guerin Vaccine Sales, Value and Gross Margin (2020-2025)
8.11.4 BioFarma Bacille Calmette-Guerin Vaccine Product Portfolio
8.11.5 BioFarma Recent Developments
8.12 Ataulpho de Paiva
8.12.1 Ataulpho de Paiva Comapny Information
8.12.2 Ataulpho de Paiva Business Overview
8.12.3 Ataulpho de Paiva Bacille Calmette-Guerin Vaccine Sales, Value and Gross Margin (2020-2025)
8.12.4 Ataulpho de Paiva Bacille Calmette-Guerin Vaccine Product Portfolio
8.12.5 Ataulpho de Paiva Recent Developments
8.13 AJ Vaccines
8.13.1 AJ Vaccines Comapny Information
8.13.2 AJ Vaccines Business Overview
8.13.3 AJ Vaccines Bacille Calmette-Guerin Vaccine Sales, Value and Gross Margin (2020-2025)
8.13.4 AJ Vaccines Bacille Calmette-Guerin Vaccine Product Portfolio
8.13.5 AJ Vaccines Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Bacille Calmette-Guerin Vaccine Value Chain Analysis
9.1.1 Bacille Calmette-Guerin Vaccine Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Bacille Calmette-Guerin Vaccine Sales Mode & Process
9.2 Bacille Calmette-Guerin Vaccine Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Bacille Calmette-Guerin Vaccine Distributors
9.2.3 Bacille Calmette-Guerin Vaccine Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.